Sutro Biopharma Stock Price, News & Analysis

Sutro Biopharma, a clinical-stage oncology company, announced its CEO Bill Newell will present at the 2022 Wells Fargo Healthcare Conference on September 9, 2022, at 10:25 a.m. ET in Boston. The presentation can be accessed via the Investor Relations section of their website, with an archived replay available for 30 days following the event. Sutro is focused on developing innovative antibody drug conjugates (ADCs), including STRO-002 for ovarian and endometrial cancers and STRO-001 for B-cell malignancies, alongside collaborations with major pharmaceutical companies.

Sutro Biopharma (NASDAQ: STRO) announced on August 16, 2022, that its Compensation Committee granted 63,000 Restricted Stock Units (RSUs) to three new employees as an inducement for their employment. The RSUs will vest over four years, with 25% vesting annually, contingent upon continued service. Sutro specializes in developing antibody drug conjugates for oncology and is advancing multiple clinical-stage products, including STRO-002 and STRO-001, targeting various cancers. The grants were in accordance with Nasdaq Listing Rule 5635(c)(4).

Sutro Biopharma, Inc. (NASDAQ: STRO) reported strong collaboration developments and financial results for Q2 2022. A partnership with Astellas involves $90 million upfront and potential milestones worth $422.5 million per product. The company received a $10 million milestone payment from Merck after dosing the first patient in a Phase 1 study. Sutro's cash and equivalents stand at $191.6 million, expected to fund operations into H1 2024. Though revenues slightly increased to $28.1 million, operating expenses rose to $47.5 million, impacted by higher R&D costs. Discussions with the FDA suggest an accelerated approval pathway for STRO-002.

Sutro Biopharma, Inc. (NASDAQ: STRO) announced that CEO Bill Newell will present at the 2022 Wedbush PacGrow Healthcare Conference on August 10, 2022, at 2:20 p.m. ET. The discussion will focus on antibody drug conjugates (ADCs), a key area of Sutro's innovation in oncology. The presentation will be accessible on the company's Investor Relations page, with an archived replay available for 30 days post-event. Sutro's pipeline includes two ADCs in clinical trials, STRO-002 for ovarian and endometrial cancers and STRO-001 for B-cell malignancies.

Sutro Biopharma (NASDAQ: STRO) announced that the first patient has been dosed in a Phase 1 study of a novel therapeutic candidate developed in collaboration with Merck. This milestone triggers a $10 million payment from Merck to Sutro. The investigational drug is designed for cancer treatment, leveraging Sutro's proprietary platforms for biologics. Sutro is also advancing other ADCs in clinical trials, targeting various cancers. CEO Bill Newell emphasized the synergy between Sutro and Merck in advancing immuno-oncology therapies.

Sutro Biopharma (NASDAQ: STRO) announced a virtual research forum set for July 20, 2022, at 4:30 PM ET, where it will unveil a new product candidate and discuss its immunostimulatory antibody-drug conjugates (iADCs). The company will also highlight enhancements to its cell-free manufacturing platform.

Sutro Biopharma is focused on developing antibody-drug conjugates (ADCs) targeting various cancers, with STRO-002 and STRO-001 currently in clinical studies.

Sutro Biopharma announced a strategic collaboration with Astellas Pharma focused on developing novel immunostimulatory antibody-drug conjugates (iADCs) for cancer treatment. The partnership aims to address the limitations of existing therapies, especially for cold tumors. Sutro will receive an upfront payment of $90 million and may be eligible for up to $422.5 million in milestone payments, along with royalties on sales. This collaboration leverages Sutro's advanced conjugation technology and Astellas' oncology R&D expertise to potentially enhance treatment options for patients who do not respond to current immunotherapies.

Astellas Pharma and Sutro Biopharma have entered a worldwide collaboration to develop immunostimulatory antibody-drug conjugates (iADCs), targeting cold tumors resistant to current therapies. Sutro will receive an upfront payment of US$90 million and could earn up to US$422.5 million in additional milestones per product. Astellas aims to enhance its oncology pipeline through this partnership, leveraging both companies' strengths in drug development and commercialization.

Sutro Biopharma (NASDAQ: STRO) announced the grant of stock options for 75,000 shares and 80,000 Restricted Stock Units (RSUs) to three new employees as an inducement for their employment. The Compensation Committee approved these grants on June 3, 2022, in accordance with Nasdaq rules. The RSUs will vest over four years, while the stock options will vest monthly after the first year. Sutro focuses on creating next-generation therapeutic solutions using its proprietary platforms, advancing several drug candidates in clinical trials for various cancers, including STRO-001 and STRO-002.